Aug. 19 at 1:38 PM
$NWBO The Merck/ Moderna combo news is a fantastic opportunity for NWBO.
Why ?
Simply because it alerts the public about important cancer treatments and their perceived valuation.
The key number to watch next for V940 / Keytruda combo against melanoma is the -yet to be published - Phase 3 HR ( Hazard Ratio ) which is extremely important to gage the efficiency of a treatment. Once Merck/Moderna release it, we can make a much more rigorous statistical comparison with DCVax-L’s 0.69–0.77 range ( that means the analyses estimated roughly a 23–31% lower rate of death over the observation period, relative to the matched external-control population.)
This is what is encouraging :
On news, Merck/ Moderna valuation jumped by a staggering
$56 Billions so far in pre market today so far whilst NWBO still crawls in the mud with sub
$300 million valuation and
$0,18/ sh.
When will the market reassess NWBO is the whole question !
